Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxybutynin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oxybutynin Chloride is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 13, 2025
Lead Product(s) : Oxybutynin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azelastine Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Azelastine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2023
Lead Product(s) : Azelastine Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elobixibat
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation
Details : Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 09, 2023
Lead Product(s) : Elobixibat
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Albuterol Sulfate is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : GCP ClinPlus | Beijing Aicomer Pharmaceutical Technology | Key Tech | Healthcare Inc | Peking University People's Hospital | Beijing Friendship Hospital | Tianjin First Central Hospital | Bao Gang Hospital | The Affiliated Hospital of Inner Mongolia Medic
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Budesonide is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
December 09, 2021
Lead Product(s) : Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : GCP ClinPlus | Beijing Aicomer Pharmaceutical Technology | Key Tech | Healthcare Inc | Peking University People's Hospital | Beijing Friendship Hospital | Tianjin First Central Hospital | Bao Gang Hospital | The Affiliated Hospital of Inner Mongolia Medic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Decoy20,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $30.0 million
Deal Type : Private Placement
Intec Announces $30 Million Private Placement Ahead of Decoy Merger
Details : Decoy20 is single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
July 26, 2021
Lead Product(s) : Decoy20,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $30.0 million
Deal Type : Private Placement
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Albuterol Sulfate is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 03, 2021
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Albuterol Sulfate is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2021
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Budesonide is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
July 31, 2020
Lead Product(s) : Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Budesonide is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 01, 2016
Lead Product(s) : Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable